endometrial hyperplasia
Conditions
Interventions
Experimental group:treated with progesterone combined with metformin
Control group:Oral progesterone
Sponsors
GuangDong Women and Children Hospital
Eligibility
Sex/Gender
Female
Age
20 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. Diagnostic curettage is performed due to "abnormal uterine bleeding", and the pathological diagnosis is endometrial hyperplasia; 2. Aged 20-45 years, willing to participate in the study and sign the consent form; 3. Patients with atypical endometrial hyperplasia who require fertility preservation and refuse to remove the uterus.
Exclusion criteria
Exclusion criteria: 1. Have used metformin or hormone drugs in the past 6 months; 2. Have serious liver dysfunction, renal dysfunction, cardiovascular and cerebrovascular diseases in the past; 3. Have contraindications of using metformin; 4. Have family history or history of thrombosis; 5. The pathological results of endometrial carcinoma; 6. Diabetic patients who need insulin injection; 7. Have other malignant tumors of reproductive system.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression rate;PR expression;TGF-1 expression;TGF-1R expression;AMPK expression;mTOR expression; | — |
Secondary
| Measure | Time frame |
|---|---|
| androgen;Glucose metabolism index;Lipid metabolism index; | — |
Countries
China
Contacts
Public ContactFan Yu
Department of Gynecology, GuangDong Women and Children Hospital
Outcome results
None listed